Skip to content

Development of the rehabilitation nursing support program using tele-nursing systems for pancreatic cancer patients: A pilot study

Development of a rehabilitation nursing support program using tele-nursing systems for pancreatic cancer patients: A pilot study - Pancreatic cancer tele-nursing rehabilitation trial - pilot study -

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000055794
Enrollment
50
Registered
2024-10-10
Start date
2025-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Daily exercises are carried out at home via video or self-directed training at least twice a week, and telenursing support is provided once every four weeks.

Sponsors

Fukushima Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who have been clinically diagnosed with pancreatic cancer (including IPMC) and are planning to undergo surgery. 2. Patients undergoing initial treatment 3. Patients with a PS (ECOG classification) of 0 to 1 4. Patients with preserved function of major organs (bone marrow, liver, kidneys, lungs, etc.) 5. Patients who can take food orally 6. Patients who can use a tablet or smartphone and have a good internet connection at home 7. Patients who have given written consent to be subjects of this study 8. Adults aged 18 years or older at the time of consent acquisition who have sufficient judgment to give consent to this study 9. Patients who have received a sufficient explanation of the contents of this study and have given written consent

Exclusion criteria

Exclusion criteria: 1. Patients with pulmonary fibrosis or interstitial pneumonia 2. Patients with macroscopic residual cancer at the time of resection 3. Patients with active overlapping cancers 4. Patients with active infections 5. Patients with positive HBs antigen 6. Patients using flucytosine, phenytoin, or warfarin 7. Patients who are pregnant or may be pregnant 8. Patients who are otherwise deemed unsuitable by the attending physician to safely conduct this study

Design outcomes

Primary

MeasureTime frame
Patient adherence to the program 6 months after surgery

Secondary

MeasureTime frame
Validity (changes from baseline at 3 and 6 months in grip strength, knee extension strength, 6-minute walk, EORTC-C30, FACT-Hep, SDS, etc.) and safety (incidence of adverse events over the entire study period)

Countries

Japan

Contacts

Public ContactNaoko Sato

Fukushima Medical University Faculty of Nursing

naoko-st@fmu.ac.jp0245471858

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026